Michael A. Weber, MD, an investigator in the PRECISION study, discusses the newly FDA approved drug aprocitentan (Tryvio), and its promise for helping patients with treatment-resistant hypertension.
Chris Mazzolini
Advertisement
Articles by Chris Mazzolini
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Patient Care Online
1
Colorectal Cancer Becomes Leading Cause of Cancer Death in US Adults Younger Than 50 Years, Study Finds
2
Investigational Dual GLP-1/GIP Agonist CT-388 Demonstrates 22.5% Placebo-Adjusted Weight Loss in Phase 2 Obesity Trial
3
Centanafadine Granted FDA Priority Review for the Treatment of ADHD Across Pediatric and Adult Populations
4
FDA Approves Updated Prescribing Information for Inhaled Insulin Powder, Including New Starting Dose Guidance
5